The average read-out from conventional bulk sequencing misses the rare events and underlying genetic diversity within and across cell populations. To resolve tumor heterogeneity and improve patient stratification, therapy selection, and disease monitoring we need insights into clonal architecture and mutation co-occurrence within every single cell.